FDA Releases 2021 Report on Fatalities Following Blood ...

Deaths reported to the FDA include donor fatalities, recipient fatalities in which allogeneic blood transfusion (ABT) was not deemed to be the likely or major ...

由 EK Storch 著作 · 2020 · 被引用 31 次 — Most ABO-incompatible RBC transfusions are not fatal but may be associated with significant complications. In our preliminary analysis of ...

由 EK Storch 著作 · 2020 · 被引用 31 次 — The rate of reported fatalities from ABO-incompatible RBC transfusion has significantly decreased in the past decade.

由 MV Jadhav 著作 · 2000 · 被引用 6 次 — 3 deaths could not be attributed to transfusion reaction. Post transfusion endotoxaemia (7 cases) was the most frequent mode of transfusion associated fatality ...

2023年9月29日 — In FY 2021, the leading cause of transfusion-related fatalities was transfusion-associated circulatory overload (TACO), accounting for 36 ...

Fatalities previously defined as not transfusion/donation related continue to be classified as ruled out. To achieve a more comprehensive review, we added three ...

2023年9月22日 — Annual Summary Fatalities Reported to FDA Following Blood Collection and Transfusion older than 2 years are available on FDA ArchiveExternal ...

Immunologic Complications, Immediate. 1. Hemolytic transfusion reaction (incidence: 1:12,000 to 1:38,000). 2. Immune mediated platelet destruction ...